THU0245 Post-Vaccinal Arthritis in an Ebola Vaccine Trial with a Live-Attenuated Recombinant Virus Expressing the Ebola Surface Glycoprotein (RVSV-ZEBOV)
Axel Finckh(University Hospital of Geneva), C.-A. Siegrist(University Hospital of Geneva), Cem Gabay(Hôpital Beau-Séjour), Ilias Lazarou(Center for Rheumatology), L. Tapparel(Center for Rheumatology), Julie-Anne Dayer(Flinders University), Isabelle Fabreguet(Center for Rheumatology), Juan Enrique Berner(Center for Rheumatology), Laurent Kaiser(University Hospital of Geneva), Angela Huttner(University Hospital of Geneva), Sabine Yerly(Unknown)
Cited by 2
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
Interleukin-6 and chronic inflammation.
|Arthritis Research & Therapy|2006|1.4k
IL‐1, IL‐18, and IL‐33 families of cytokines
|Immunological Reviews|2008|899